News

Ad hoc announcement pursuant to Art. 53 LR

medmix strengthens profitability and cash flow while advancing growth and efficiency initiatives

medmix introduces FleXa™, a new customizable syringe platform that advances precision and branding for single-component dental materials.

At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.10 per share.

medmix has been included in the 2026 edition of the “World’s Best Companies in Sustainable Growth”, a global ranking compiled by TIME Magazine in collaboration with data and research firm Statista.

Ad hoc announcement pursuant to Art. 53 LR

Resilient Performance with Strong Profit Gains in Challenging Markets

medmix’ Drug Delivery (“Haselmeier”) showcased the proven innovation behind its PiccoJect™ platform for high-viscosity drugs at the international conferences PDA Universe in Vienna and PODD in Boston.

medmix wins one of the largest new Beauty businesses in company history and strengthens position in key global beauty markets with facility extensions

medmix has partnered with Gurit, a global leader in advanced composite materials, to advance sustainable solutions for industrial bonding applications.

Ad hoc announcement pursuant to Art. 53 LR

Increased profitability despite subdued revenues

medmix has been recognized as one of only nine Swiss companies to achieve an "A" score in CDP's annual climate change assessment, placing it in a select group of global environmental leaders

At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share.

Ad hoc announcement pursuant to Art. 53 LR

Robust performance in challenging market environment